GCC Fabry sizing methods disagree by a 3-5x margin, and the gap traces to two named causes: single-laboratory diagnostic gating and a female diagnosis rate under half the male rate.
The registry method counts confirmed diagnoses: NPHC and specialist genetics registries across the GCC track approximately 200-300 diagnosed Fabry patients. The epidemiology method starts from Arabian Peninsula founder mutations documented at KFSH&RC, which create family clusters of four to eight affected males across two to three generations, and estimates classic Fabry male prevalence at 1:20,000-30,000 across the GCC, elevated above the roughly 1:40,000 global rate by regional consanguinity. Triangulating the two methods does not average them; it puts true GCC Fabry prevalence at an estimated 3-5 times the diagnosed registry count, identifying the gap itself as the addressable undiagnosed population.
That gap has two specific, verifiable causes. The first is diagnostic capacity for confirming treatment eligibility rather than diagnosis itself: the HEK293 cell-based assay needed to confirm an amenable GLA mutation runs at a single laboratory across all six GCC states, KFSH&RC, leaving an estimated 80% of potentially amenable patients untested and, by extension, likely undercounted in registries that lean on confirmed-eligibility records. The second is a sex-specific diagnosis gap: estimated female Fabry patients in the GCC run 2-3 times the male burden, since heterozygous women rarely undergo cascade screening after a male relative's diagnosis and cultural factors in some families further limit female genetic workup, yet diagnosed female cases represent fewer than half the male diagnosis rate. A sizing model built only on the registry count would understate the addressable population by exactly this combined margin, while a model built only on founder-mutation epidemiology would overstate near-term reachable patients by ignoring both bottlenecks.
GCC Fabry sizing — registry count versus founder-mutation epidemiology estimate
| Sizing Method | Population Estimate | Source |
|---|---|---|
| Registry-based (confirmed diagnoses) | 200-300 patients | NPHC and specialist genetics registries |
| Epidemiology-based (founder-mutation adjusted) | 3-5× above registry count | KFSH&RC Fabry disease registry; Al-Hassnan ZN, Saudi Med J 2010 |
| Diagnostic capacity constraint | 1 GCC laboratory (KFSH&RC) offering the HEK293 assay | KFSH&RC genetics laboratory capacity report 2023 |
| Female diagnosis gap | Under 50% of male diagnosis rate vs 2-3× estimated female burden | KFSH&RC Fabry genetics programme data; GCC lysosomal storage disorder network 2022 |
Sources: KFSH&RC Fabry disease registry 2023; Al-Hassnan ZN, Saudi Med J 2010; KFSH&RC genetics laboratory capacity report 2023; KFSH&RC Fabry genetics programme data; GCC lysosomal storage disorder network 2022; European Fabry registry GFR comparison.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NPHC and specialist registry methodology
- Arabian Peninsula founder-mutation epidemiology
- the 3-5x triangulated gap between registry count and true prevalence
Delivers
- Sensitivity ranking of every input
- why the single-laboratory HEK293 bottleneck outranks prevalence rate as the binding constraint
- the untested-patient estimate this implies
Delivers
- Female-vs-male diagnosis rate benchmarking
- the 2-3x estimated female burden ratio
- cascade-screening yield modelling for large Gulf Arab family structures
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why single-laboratory diagnostic capacity, not founder-mutation prevalence, is the assumption that determines whether the total holds up
- Pressure-tested against the registry-vs-epidemiology gap before the rest of the model is built out
- Arabian Peninsula founder-mutation prevalence (1:20,000-30,000 males)
- Family cluster structure documented at KFSH&RC
- NPHC and specialist genetics registry count (200-300 patients)
- Cross-check against founder-mutation epidemiology
- Female-vs-male diagnosis rate benchmarking (under 50% of male rate)
- The 3-5x true-vs-diagnosed prevalence ratio this implies
- Single-laboratory HEK293 capacity ranked above founder-mutation prevalence as the binding assumption
- Scenario ranges tied to assay-capacity expansion and cascade-screening uptake
- The full triangulated model, re-runnable with your own assumptions
- The open sizing questions your team must close before the number is used in planning
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx market sizing model triangulates at least two independent methods, epidemiology-based and registry-based, before accepting a patient count. This is explicitly a sizing model (static patient count), distinct from a Patient Flow or forecasting model.
GCC Fabry sizing sources: KFSH&RC Fabry disease registry 2023, Al-Hassnan ZN (Saudi Med J 2010), KFSH&RC genetics laboratory capacity report 2023, KFSH&RC Fabry genetics programme data, and the GCC lysosomal storage disorder network 2022.
- Diagnosed registry count and founder-mutation prevalence verified against KFSH&RC Fabry disease registry 2023 and Al-Hassnan ZN, Saudi Med J 2010
- Single-laboratory HEK293 assay bottleneck verified against KFSH&RC genetics laboratory capacity report 2023
- Female diagnosis gap figures verified against KFSH&RC Fabry genetics programme data and GCC lysosomal storage disorder network 2022
Frequently asked questions
Commission this model
AXLRx delivers rare disease market sizing models built for forecasting and strategy teams sizing the GCC Fabry opportunity. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms triangulation methods and comparator set before building.
Research-verified sizing model in 72 hours with optional analyst readout.